There are currently 1266 clinical trials in Nashville, Tennessee looking for participants to engage in research studies. Trials are conducted at various facilities, including Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University and Sarah Cannon Research Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases
NCT05357612
Recruiting
It is hypothesize that patients with clinically diagnosed neurodegenerative diseases will have significantly different receptor occupancy of 5HT2A receptors compared to a healthy age/sex-matched control group. This will be tested by measuring 5HT2A receptor density using the PET radioligand (R)-\[18F\]MH.MZ in both populations.
Gender:
ALL
Ages:
Between 50 years and 85 years
Trial Updated:
02/27/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Neurodegenerative Diseases, Parkinson Disease, Parkinson Disease Psychosis
Register for Updates
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
NCT01574053
Recruiting
Enroll-HD is a longitudinal, observational, multinational study that integrates two former Huntington's disease (HD) registries-REGISTRY in Europe, and COHORT in North America and Australasia-while also expanding to include sites in Latin America. More than 30,000 participants have now enrolled into the study. With annual assessments and no end date, Enroll-HD has built a large and rich database of longitudinal clinical data and biospecimens that form the basis for studies developing tools and b... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Huntington's Disease
Register for Updates
Tranexamic Acid in Rhinoplasty: Perioperative Bleeding, Edema and Ecchymosis
NCT05774717
Recruiting
This study will be a prospective randomized study to evaluate the effect of tranexamic acid (TXA) use on intraoperative and postoperative outcomes among patients undergoing rhinoplasty by two Facial Plastic surgeons at Vanderbilt. Outcomes will include intra- and post-operative bleeding and postoperative bruising and swelling.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Surgery, Postoperative Blood Loss
Register for Updates
SOUND Pivotal Trial - (Sonomotion stOne comminUtion resoNance ultrasounD)
NCT05701098
Recruiting
The goal of this clinical trial is to test the Break Wave™ system in patients with upper urinary tract stones. The main question it aims to answer is whether the device is safe and effective in fragmenting (breaking) stones. Participants will a) undergo the Break Wave™ procedure, b) have a telehealth visit at 2 weeks, and c) return for an imaging study at approximately 10 weeks post-procedure.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/23/2024
Locations: Vanderbilt University, Nashville, Tennessee
Conditions: Kidney Stone, Urolithiasis, Nephrolithiasis, Renal Calculi, Kidney Calculi, Nephrolith, Urinary Calculi
Register for Updates
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
NCT05366881
Recruiting
This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gastric, head and neck, hepatobiliary, leukemia, lung, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, renal, sarcoma, and thyroid. These cancers were selected based on their prevalence and mort... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
02/15/2024
Locations: Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
Conditions: Brain Cancer, Breast Cancer, Bladder Cancer, Cervical Cancer, Colorectal Cancer, Endometrial Cancer, Esophageal Cancer, Stomach Cancer, Head and Neck Cancer, Hepatobiliary Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cancer, Sarcoma, Thyroid Cancer
Register for Updates
ELUCIDATE FFRct Study
NCT06018194
Recruiting
The goal of this study is to evaluate the diagnostic accuracy of a novel plaque-based coronary CT angiography (CCTA) fractional flow reserve (FFRct) software device for the estimation of invasive fractional flow reserve (FFR). Researchers will compare the Elucid plaque-based FFRct analysis to invasively measured FFR in patients who have previously undergone CCTA and invasively assessed FFR.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/15/2024
Locations: Centennial Heart, Nashville, Tennessee +1 locations
Conditions: Coronary Artery Disease
Register for Updates
Storage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of Treatment
NCT01205815
Recruiting
The purpose of this research is to identify biological characteristics occurring in the initiation and progression of melanoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2024
Locations: Vanderbitl-Ingram Cancer Center, Nashville, Tennessee
Conditions: Melanoma
Register for Updates
Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer
NCT05654532
Recruiting
This clinical trial is evaluating a drug called AC699 in participants with estrogen receptor positive/human epidermal growth factor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer. The main goals of this study are to: * Identify the recommended dose of AC699 that can be given safely to participants * Evaluate the safety profile of AC699 * Evaluate the pharmacokinetics of AC699 * Evaluate the effectiveness of AC699
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2024
Locations: Site 01, Nashville, Tennessee
Conditions: Breast Cancer
Register for Updates
Tennessee Youth Prepared for Success
NCT06001892
Recruiting
The principal objective of Tennessee Youth Prepared for Success is to pilot, implement, and test innovative adolescent pregnancy prevention strategies using a randomized controlled trial (RCT) to effectively educate youth on both abstinence and contraception with the goal of reducing youth pregnancies, births, and STIs. Tennessee Youth Prepared for Success will address Adulthood Preparation Subjects (APS) to promote youths' successful and healthy transition to adulthood; include a Positive Youth... Read More
Gender:
ALL
Ages:
Between 14 years and 19 years
Trial Updated:
02/05/2024
Locations: Centerstone Research Institute, Nashville, Tennessee
Conditions: Adolescent Behavior, Adolescent Problem Behavior, Risk Reduction
Register for Updates
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
NCT04137900
Recruiting
The primary objective is to assess the safety and tolerability of TAB004 as monotherapy and in combination with toripalimab in subjects with selected advanced solid malignancies, including lymphoma, and to evaluate the recommended Phase 2 dose. The secondary objectives are to: 1) describe the pharmacokinetic (PK) profile of TAB004 monotherapy and in combination with toripalimab and to describe the PK profile of toripalimab when administered with TAB004, 2) evaluate antitumor activity of TAB004... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/01/2024
Locations: Sarah Cannon Research Institute, Nashville, Tennessee
Conditions: Advanced Unresectable Solid Tumor, Metastatic Solid Tumor
Register for Updates
Physiologic Pacing for Symptomatic First-Degree Heart Block
NCT06245304
Recruiting
The purpose of this study is to determine if physiologic pacing will improve symptoms and outcomes in patients with symptomatic first-degree heart block (pr interval ≥250ms).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2024
Locations: Ascension Saint Thomas Midtown, Nashville, Tennessee
Conditions: Symptomatic First-degree Heart Block
Register for Updates
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
NCT04849728
Recruiting
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: NASH - Nonalcoholic Steatohepatitis
Register for Updates